Short interest for Edenred gives investors a sense of the degree to which investors are betting on the decline of Edenred's stock. Short interest data is updated every two weeks.

Edenred Stock (OTC:EDNMY), Short Interest Report

Edenred is a France-listed prepaid corporate services provider operating in more than 40 countries. The company was listed in 2010 following a spinoff from hotel group Accor. Edenred's main business, Ticket Restaurant, offers prepaid meal vouchers that employers provide to their employees as an additional benefit. The company is also involved in other areas such as prepaid fuel cards and payment and expense-management systems.

News

Intraday Update

Markets

Movers

Trading Ideas

AANNF

AAPL

ABVN

ACIA

ACIW

ACLS

ADBE

ADDDF

ADDYY

ADSK

ADUS

AEBZY

AFGC

AFGVY

AGTC

AHEXY

AILQF

AKRFF

AMADY

AMED

AMRC

ANPDF

ANSS

APAM

APLT

APPF

ARCAY

ARDC

ARES

ARGX

ARVN

ASHTF

ASHTY

ASMIY

ASML

ATGN

ATZAF

AZIHF

BABA

BILI

BIOS

BIRMF

BKNG

BKOR

BLDP

BMCH

BPOP

BRK-A

BRK-B

BTAFF

CABO

CACI

CAMT

CASH

AllianzGI Convertible & Income 2024 Target Term Fund Common Shares of Beneficial Interest

CCOI

CDAY

CDLX

CFFA

CGEN

CHGCY

CHRYY

CIGI

CLGN

CLZNY

CMXHF

CNNE

COHR

COHU

COLL

Stocks That Hit 52-Week Highs On Thursday

Edenred SE

Guidance

Estee Lauder CFO Says Impact From Business Disruptions In Israel And Other Parts Of Middle East Was $0.01 Dilutive To EPS In Q3

WIIM

VRSK

Verisk Analytics shares are trading higher after the company reported better-than-expected Q1 financial results.

Mizuho analyst Vijay Rakesh maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and lowers the price target from $235 to $215.

Price Target

Analyst Ratings

Mizuho Maintains Buy on Advanced Micro Devices, Lowers Price Target to $215

ENTG

Entegris shares are trading lower after the company issued weak Q2 guidance.

Republic Services shares are trading lower following mixed Q1 earnings.

Wedbush analyst Michael Pachter reiterates Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) with a Outperform and maintains $19 price target.

Reiteration

HEAR

Wedbush Reiterates Outperform on Turtle Beach, Maintains $19 Price Target

Clean Harbors shares are trading higher after the company reported better-than-expected Q1 financial results.

Dearborn-based Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is recalling 242,669 units of its Maverick vehicles as the rear tail lights might not work.
What Happened: The Body Control Module (BCM) of these model year 2022- 2024 Maverick vehicles may deactivate one or both of the rear tail lights, thereby reducing the vehicle&#8217;s visibility to other drivers and increasing risks of a collision, U.S. auto safety regulator National Highway Traffic Safety Administration (NHTSA) said. 
As for a solution, Ford dealers will update the BCM software, NHTSA said. The fix would involve no cost to the customer. 
Ford said in a filing with the NHTSA that it is aware of 11 warranty claims potentially related to the issue as of April 4. However, it is not aware of any accidents or injuries due to it, the company added.
Why It Matters: As per data from NHTSA, <a href="https://www.benzinga.com/markets/equities/24/04/38296131/ford-recalls-456-565-suvs-and-trucks-over-low-battery-issue-nhtsa-warns-of-safety-risks-report">Ford has issued 23 recalls</a> this year- the most among automakers- potentially affecting about 2.9 million vehicles. 
In comparison, General Motors has issued 6 recalls while Stellantis has issued 20 in the United States. 
NHTSA also<a href="https://www.benzinga.com/markets/equities/24/04/38493842/fords-bluecruise-under-nhtsa-lens-after-fatal-crashes-report"> launched an investigation </a>into Ford&#8217;s hands-free driving technology BlueCruise earlier this week after an initial investigation into two fatal crashes involving Ford Mustang Mach-E vehicles confirmed that the tech was engaged immediately before the collision. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/markets/asia/24/05/38547116/xpeng-boss-welcomes-teslas-fsd-china-entry-with-open-arms-sees-it-driving-entire-industry-forward">Xpeng Boss Welcomes Tesla&#8217;s FSD China Entry With &#8216;Open Arms,&#8217; Sees It Driving &#8216;Entire Industry Forward&#8217;</a>
Photo via Wikimedia Commons

Tech

Ford Recalls Nearly 243,000 Maverick Trucks Due To Rear Tail Light Concerns

Global Payments shares are trading lower after the company reported Q1 financial results and issued guidance.

Biotech

Rumors

General

TGTX

Watching TG Therapeutics; Hearing M&A Blog Says Strong Sales Forecast For Multiple Sclerosis Drug That May Draw Suitors

The Carlyle Group shares are trading lower after the company reported Q1 financial results.

Wedbush analyst Michael Pachter reiterates FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Outperform and maintains $5 price target.

FUBO

Wedbush Reiterates Outperform on FuboTV, Maintains $5 Price Target

CDW shares are trading lower after the company reported worse-than-expected Q1 financial results.

Jefferies analyst Andy Barish maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and lowers the price target from $94 to $84.

SBUX

Jefferies Maintains Hold on Starbucks, Lowers Price Target to $84

Piper Sandler analyst Brian Mullan maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Neutral and lowers the price target from $84 to $82.

Piper Sandler Maintains Neutral on Restaurant Brands Intl, Lowers Price Target to $82

GRMN

Garmin shares are trading higher after the company reported better-than-expected Q1 financial results and affirmed FY24 adjusted EPS and sales guidance, which is above estimates.

In the preceding three months, 23 analysts have released ratings for Eli Lilly and Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Eli Lilly and Co, presenting an average target of $833.91, a high estimate of $1000.00, and a low estimate of $630.00. Marking an increase of 14.42%, the current average surpasses the previous average price target of $728.79. 
<img src="https://www.benzinga.com/files/images/story/2024/1714572065_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Eli Lilly and Co among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$892.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$885.00</td>
<td>$815.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$723.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$895.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$850.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$850.00</td>
<td>$775.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$1000.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Elmar Kraus</td>
<td>DZ Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$820.00</td>
<td>-</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$950.00</td>
<td>$805.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$815.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$850.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>David Phung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$805.00</td>
<td>$763.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$810.00</td>
<td>$680.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$825.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$865.00</td>
<td>$710.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$825.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$815.00</td>
<td>$630.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$630.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eli Lilly and Co. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly and Co compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Eli Lilly and Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Eli Lilly and Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eli Lilly and Co analyst ratings.</a>
<h2>All You Need to Know About Eli Lilly and Co</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
<h3>Eli Lilly and Co's Economic Impact: An Analysis</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Eli Lilly and Co displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 28.1%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Eli Lilly and Co's net margin excels beyond industry benchmarks, reaching 23.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eli Lilly and Co's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 19.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Eli Lilly and Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: Eli Lilly and Co's debt-to-equity ratio is below the industry average at 2.34, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 23 Analyst Ratings Have To Say About Eli Lilly and Co

With rent for multifamily properties in Austin, Texas, falling 6.2% from last year, real estate mogul Grant Cardone has declared the city is undergoing a real estate correction.
In an April 30<a href="https://twitter.com/GrantCardone/status/1785302632942243870"> post on X</a>, Cardone said the city faces an oversupply challenge, with 18.9% of apartments either under construction or in the lease-up phase.
"The real estate correction is underway, and it will create a 10x opportunity for long-term investors," Cardone posted.
Still, there are pockets of Austin that have demonstrated notable resilience and growth. Lake Travis and far North Austin, for example, experienced a 20 basis-point increase, reaching 95.8% occupancy — the highest in the market.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
In November, Cardone told Moneywise he wouldn't touch the Austin real estate market because of the glut of available apartments.
"Austin, Texas, is one of the worst markets to be in right now," he said at the time. "Of all the markets in America, it's probably the most overbuilt."
Cheryl Higley, managing director of debt and equity for Northmarq's Austin office, recently told REjournals that the Austin multifamily sector is experiencing oversupply driven largely by construction in recent years.
"This oversupply has led to vacancy rates reaching a 20-year high. However, there are indications that the market will gradually balance out in the long run," Higley said.
Trending:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
Multifamily developers are chasing Austin's booming population of young adults aged 20 to 34, an age group that's expected to grow 1.8% this year.&nbsp;&nbsp;
"Given that this age group is more inclined towards renting rather than homeownership, the continued influx of young adults into the city, in addition to the expected drop-off in new units, suggests a more balanced multifamily market in the long run," Higley said.
The age group is likely drawn to the city not just for its hip vibe and cool music scene but also for its status as a top tech hub with high-paying jobs.
Last year, Austin ranked among the<a href="https://www.benzinga.com/real-estate/23/11/35873987/boomtown-rising-unveiling-the-next-austin"> top targets</a> for commercial real estate investment, taking the No. 2 spot for the second consecutive year in CBRE's<a href="https://www.cbre.com/insights/briefs/2023-us-investor-intentions-survey-less-investment-activity-expected"> 2023 U.S. Investor Intentions survey</a>. Its job and office rent growth placed the city second among North America's 30 hottest tech hubs.
Read Next:
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>
Image Credit: YouTube

Real Estate

Grant Cardone Says Austin Real Estate Market Correction Presents '10x Opportunity' For Investors

MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $46.25, a high estimate of $49.00, and a low estimate of $43.00. This current average has increased by 5.71% from the previous average price target of $43.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1714572054_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of MPLX among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Reynolds</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Parkhill</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MPLX. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MPLX compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of MPLX's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of MPLX's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MPLX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MPLX analyst ratings.</a>
<h2>Unveiling the Story Behind MPLX</h2>
MPLX LP is a partnership that owns both pipelines and gathering and processing assets with extensive holdings in the Appalachian region. The asset base is made up of pipeline assets dropped down from Marathon Petroleum, its sponsor, and gathering and processing assets from MarkWest, which it acquired in 2015. MPLX also acquired Andeavor Logistics in July 2019.
<h3>MPLX's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: MPLX's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 6.96%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: MPLX's net margin excels beyond industry benchmarks, reaching 41.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MPLX's ROE stands out, surpassing industry averages. With an impressive ROE of 16.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MPLX's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.06% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.57.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPLX

Analyst Scoreboard: 4 Ratings For MPLX

Warning: EDNMY is at high risk of performing badly

Warning: EDNMY is at high risk of cutting its dividend

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

ClearBridge International Growth EAFE Strategy Q1 2024 Portfolio Manager Commentary